Research programme: oxazole compounds - Otsuka PharmaceuticalAlternative Names: 453150; PDE4 inhibitors - Otsuka Pharmaceutical
Latest Information Update: 16 Jul 2016
At a glance
- Originator Otsuka Pharmaceutical
- Mechanism of Action Tumour necrosis factor alpha inhibitors; Type 4 cyclic nucleotide phosphodiesterase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Atopic dermatitis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Atopic-dermatitis in Japan (Transdermal)